The IPSS mean change from baseline to end point was -3.46.8 in the placebo group and -1.36.6 , -2.67.0 , -3.76.7 and -4.45.7 in the 1 , 3 , 10 and 25mg LY500307-treated groups , respectively ( P > 0.05 ) .